Helping to Bring Improved and Novel Therapies to the Right Patient Population Faster
Helping to Bring Improved and Novel Therapies to the Right Patient Population Faster
Expansion of ResidenceTimer™ kinase panel
Determination of target residence time may help you to differentiate your drug candidate from competitor compounds. Drugs that reside on their target for several […]
Compound profiling on EGFR mutants and osimertinib-resistant cell lines
Mutations in the epidermal growth factor receptor (EGFR) are the most common oncogenic drivers in non-small cell lung cancer (NSCLC), but many patients treated […]
Cancer cell panel profiling of MAPK pathway inhibitors
The MAPK signal transduction pathway plays a key role in tumor progression. Mutations in the corresponding driver genes, such as KRAS and BRAF, are […]
Compound profiling in PARP inhibitor-resistant cancer cell lines
Drug resistance is a major problem in the treatment of cancer. Many aspects of clinical drug resistance can be studied in drug-resistant cell lines […]
